Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
1. A method for treating hepatitis C in a host in need thereof comprising administering an anti-HCV effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
2. The method of claim 1 , comprising an anti-HCV effective amount of a compound of the formula:
3. The method of claim 1 , comprising an anti-HCV effective amount of a compound of the formula:
4. The method of claim 1 , wherein the compound is administered orally.
5. The method of claim 4 , wherein the compound is administered in a tablet or a capsule.
6. The method of claim 1 , wherein the host is a human.
7. The method of claim 2 , wherein the compound is administered orally.
8. The method of claim 7 , wherein the compound is administered in a tablet or a capsule.
9. The method of claim 2 , wherein the host is a human.
10. The method of claim 3 , wherein the compound is administered orally.
11. The method of claim 10 , wherein the compound is administered in a tablet or a capsule.
12. The method of claim 3 , wherein the host is a human.
13. A method for treating hepatitis C in a host in need thereof comprising administering an anti-HCV effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
14. The method of claim 13 , comprising an anti-HCV effective amount of a compound of the formula:
15. The method of claim 13 , comprising an anti-HCV effective amount of a compound of the formula:
16. The method of claim 13 , wherein the compound is administered orally.
17. The method of claim 16 , wherein the compound is administered in a tablet or a capsule.
18. The method of claim 13 , wherein the host is a human.
19. The method of claim 14 , wherein the compound is administered orally.
20. The method of claim 19 , wherein the compound is administered in a tablet or a capsule.
21. The method of claim 14 , wherein the host is a human.
22. The method of claim 15 , wherein the compound is administered orally.
23. The method of claim 22 , wherein the compound is administered in a tablet or a capsule.
24. The method of claim 15 , wherein the host is a human.